GlassScriptPhysician profile
Ami Kavi Edwards
NPI 1619920220
$2,717.68
in general payments reported to CMS, 2019-2025
32 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $81.74 · 2021: $321 · 2022: $629 · 2023: $591 · 2024: $476 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.36 | 2020-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $221.67 | 2020-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $206.95 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $197.16 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Sumitomo Pharma America, INC. | $143.59 | 2023-2025 | Gemtesa |
| Pfizer INC. | $142.18 | 2019-2023 | |
| Lilly USA, LLC | $127.20 | 2021-2024 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $86.85 | 2024-2025 | Eliquis |
| Boston Scientific Corporation | $76.56 | 2024-2025 | General - Pain Management, Watchman Flx |
| Sunovion Pharmaceuticals INC. | $50.17 | 2022 | |
| Amgen INC. | $47.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.99 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $40.22 | 2019 | |
| Abbott Laboratories | $39.84 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $38.61 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.47 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.38 | 2025 | |
| Si-Bone, INC. | $23.00 | 2023 | |
| Corcept Therapeutics | $22.51 | 2022 | |
| Dexcom, INC. | $20.96 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $19.24 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.54 | 2024 | Caplyta |
| Astellas Pharma US INC | $18.33 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $18.30 | 2023 | Auvelity |
| Amarin Pharma, INC. | $14.53 | 2020 | |
| Ferring Pharmaceuticals INC. | $13.79 | 2023 | Rebyota |
| Shire North American Group INC | $13.44 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2022 | |
| Sanofi Pasteur INC. | $12.32 | 2021 | |
| Therapeuticsmd, INC. | $11.92 | 2022 | |
| Inogen, INC. | $10.13 | 2023 | Inogen One G3 Oxygen Concentrator |
| Endogastric Solutions, INC | $8.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.